Caliway
康霈生技股份有限公司
Caliway is a Taiwan TWSE-listed biotechnology company; its most advanced asset is CBL-514 (Phase 3; first participant dosed, Large-area abdominal fat reduction), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CBL-514 | — | Phase 3; first participant dosed | Large-area abdominal fat reduction | North America | 2026-09-23 | Company disclosure |
| CBL-514 + tirzepatide | — | Phase 2 IND authorized | Abdominal subcutaneous fat reduction in overweight or obese adults | United States | 2026-08-24 | Company disclosure |
Key events
- CBL-514 global Phase 3 SUPREME-01 first participant dosed announced (company disclosure)
- CBL-514 Phase 2 study in Dercum's disease met its primary efficacy endpoint (company disclosure)
- CBL-514 plus tirzepatide Phase 2 IND authorized by FDA (company disclosure)